Ò©Îïɸѡ¹ÜÀíϵͳ
Ò©Îïɸѡ¹ÜÀíϵͳ
Ò©Îïɸѡ¹ÜÀíϵͳ
ÐÂÒ©Ñо¿ÊôÓڸ߿Ƽ¼ÁìÓò,ÊÀ½ç¸÷¹ú¶ÔÐÂÒ©Ñо¿µÄͶÈëÖðÄêÔö¼Ó¡£¾Ýͳ¼Æ,1981ÄêÈ«ÊÀ½ç¶Ôr&dͶÈëΪ52ÒÚÃÀÔª,ÖÁ1996 ÄêÒÑ´ïµ½450ÒÚÃÀÔª¡£ËäÈ»ÐÂÒ©Ñо¿¿ª·¢µÄͶÈëÖðÄêÔö¼Ó,µ«Ã¿ÄêÉÏÊеÄеÄÒ»ÀàÐÂÒ©(nce)È´ÖðÄê¼õÉÙ,60Äê´ú³õÆÚ,ÿÄêÉÏÊеÄnceÔ¼100 ¸ö,1996Äê½ö40¸ö,Óɴ˿ɼû£¬Æ½¾ùÿһ¸öÐÂÒ©µÄ³É±¾Òà´ó·ù¶ÈµÄÔö¼Ó¡£
ÈËÀà»ùÒò×é¼Æ»®µÄÍê³ÉÒÔ¼°ºóÐø¹¦ÄÜ»ùÒò×é(½á¹¹»ùÒò×é¡¢µ°°×ÖÊ×éºÍ´úл×éµÈ)¼Æ»®µÄʵʩ,Éî¿ÌµØ¸Ä±äÁËÒ©ÎïÑо¿ºÍ¿ª·¢µÄ˼·¼°²ßÂÔ,ÐγÉÁËÐÂÒ©Ñо¿µÄÐÂģʽ--´Ó»ùÒò×éµ½Ò©Îï(fromgenome to drug)£¬°üÀ¨Ð°бêµÄ·¢ÏÖÓëÈ·Ö¤¡¢Ïȵ¼»¯ºÏÎïµÄ·¢ÏÖÓëÓÅ»¯ÒÔ¼°Ò©Î↑·¢¡£ÆäÖУ¬Ïȵ¼»¯ºÏÎïµÄ·¢ÏÖ¹ý³ÌÖУ¬³£ÓõÄɸѡ·½Ê½ÓиßͨÁ¿É¸Ñ¡(high throughput screening£¬hts)ºÍÐéÄâɸѡ(virtual screening£¬vs)¡£
¸ßͨÁ¿É¸Ñ¡(high throughput screening£¬hts)¼¼ÊõÊÇÒÔ·Ö×ÓˮƽºÍϸ°ûˮƽµÄʵÑé·½·¨Îª»ù´¡£¬ÒÔ΢°åÐÎʽ×÷ΪʵÑ鹤¾ßÔØÌ壬ÒÔ×Ô¶¯»¯²Ù×÷ϵͳִÐÐÊÔÑé¹ý³Ì£¬ÒÔÁéÃô¿ìËٵļì²âÒÇÆ÷²É¼¯ÊµÑé½á¹ûÊý¾Ý£¬ÒÔ¼ÆËã»ú·ÖÎö´¦ÀíʵÑéÊý¾Ý£¬ÔÚͬһʱ¼ä¼ì²âÊýÒÔǧÍòµÄÑùÆ·£¬²¢ÒԵõ½µÄÏàÓ¦Êý¾Ý¿âÖ§³ÖÔËתµÄ¼¼ÊõÌåϵ£¬¼òÑÔÖ®¾ÍÊÇ¿ÉÒÔͨ¹ýÒ»´ÎʵÑé»ñµÃ´óÁ¿µÄÐÅÏ¢£¬²¢´ÓÖÐÕÒµ½ÓмÛÖµµÄÐÅÏ¢¡£
µ«´«Í³µÄ¸ßͨÁ¿É¸Ñ¡Óöµ½Ðí¶àÎÊÌ⣬һÊÇÒ©Àí²âÊÔ¼ÙÑôÐÔÓë¼ÙÒõÐÔ½á¹û£»¶þÊÇ»¯ºÏÎïÑùÆ·À´Ô´¶Ìȱ£»ÈýÊÇͨÓÃÐÔ²»¸ß£¬ºÜ¶àhts·½·¨Ö»¶ÔÒ»ÖÖ»ò¼¸ÖÖø¾ßÓÐÊÊÓ¦ÐÔ£»Ëĺܶà¸ßͨÁ¿É¸Ñ¡·½·¨ÖÐËùÓõ½µÄÊÔ¼ÁºÍÒÇÆ÷¶¼·Ç³£°º¹ó£¬ºÜ¶àʵÑéÊÒ¶¼ÎÞ·¨Å䱸£¬¶øÓë´óÐÍÖÆÒ©ÆóÒµÏà±È£¬´ó²¿·Ö¿ÆÑе¥Î»Ã»ÓÐÕâÑùµÄ¾¼ÃʵÁ¦¡£
ÄÇÓÐʲô¸üΪ¸ßЧ¾¼ÃµÄ°ì·¨ÄØ£¿ÇÒ¿´Ñо¿Ô±domanÈçºÎ½â¾ö£º
domanµÈ[1]Ñо¿Ô±ÏëÑ°ÕÒiiÐÍÌÇÄò²¡°Ðµãµ°°×ÀÒ°±ËáÁ×Ëáõ¥Ã¸1b£¨ptp1b£©µÄÒÖÖƼÁ¡£Ê×ÏÈ£¬Ñо¿ÈËÔ±²ÉÓÃÁ˸ßͨÁ¿É¸Ñ¡µÄ·½·¨£¬Ö±½Ó½øÐÐÉúÎïѧ²âÊÔ£¬ÅúÁ¿É¸Ñ¡ÁË40Íò¸ö»¯ºÏÎµÃµ½ÁË6¸ö»îÐÔСÓÚ10¦ÌmµÄ»¯ºÏÎËæºóÑо¿ÈËÔ±²ÉÓÃÁËÐéÄâɸѡµÄ·½·¨£¬´Ó40Íò¸ö»¯ºÏÎïÔ¤²â²¢ÌôÑ¡³öÆäÖеÄ365¸ö»¯ºÏÎï½øÐÐÉúÎïѧ²âÊÔ£¬´Ó¶øµÃµ½21¸ö»îÐÔСÓÚ10¦ÌmµÄ»¯ºÏÎÁ½ÖÖ·½·¨µÄ½á¹ûÁÐÓÚͼ¡£´ÓÖпÉÒÔ¿´µ½£¬¾¹ýÐéÄâɸѡºóÔÙ½øÐÐÉúÎïѧ²âÊÔ£¬Æä¡°ÃüÖÐÂÊ¡±±ÈËæ»úµÄ¸ßͨÁ¿É¸Ñ¡Ìá¸ßÁË400±¶¡£
£¨ps£º¸ßͨÁ¿É¸Ñ¡ÓëÐéÄâɸѡÔÙÉúÎïѧ²âÊԵķ½·¨ÂÔÓв»Í¬£¬ÐéÄâɸѡÔÙÉúÎïѧ²âÊԵIJâÊÔÌõ¼þ²»°üÀ¨albumin£¬¹Êµ¼Ö½á¹ûÆ«¸ß£©
ÉÏÊöÑо¿ËµÃ÷£¬ÐéÄâɸѡ·½·¨´ó´óÌá¸ßÒ©Îï·¢ÏֵĸÅÂÊ£¬²¢½µµÍÁËÑз¢³É±¾¡£ÄÇʲôÊÇÐéÄâɸѡÄØ£¿¡ª¡ªÐéÄâɸѡ(virtual screening£¬vs)ÊÇÖ¸»ùÓÚÒ©ÎïÉè¼ÆÀíÂÛ£¬½èÖú¼ÆËã»úµÄ¼¼ÊõºÍרҵӦÓÃÈí¼þ£¬´Ó´óÁ¿»¯ºÏÎïÖÐÌôÑ¡³öһЩÓÐÃçÍ·µÄ»¯ºÏÎ½øÐÐʵÑé»îÐÔÆÀ¼ÛµÄÒ»ÖÖ·½·¨¡£ÆäÄ¿µÄÊÇ´Ó¼¸Ê®¸öÄËÖÁ°ÙÍò¸ö·Ö×ÓÖÐɸѡ³öеÄÏȵ¼»¯ºÏÎï¡£ÕâÖÖÒ©Îïɸѡ·½Ê½²»ÏûºÄÑùÆ·£¬½µµÍÁËɸѡµÄ³É±¾£¬»¹¿¼ÂÇ»¯ºÏÎï·Ö×ÓÒ©¶¯Ñ§ÐÔÖʺͶ¾ÐÔ£¬Ôö¼ÓɸѡµÄÄÚº¡£²¢ÇÒËõ¶ÌÁËÐÂÒ©Ñз¢ÖÜÆÚ£¬½µµÍÁËÖ±½ÓÑз¢·ÑÓã¬Ïà±ÈÓÚ¸ßͨÁ¿É¸Ñ¡£¬ÐéÄâɸѡ²»´æÔÚÑùÆ·ÏÞÖÆ¡£
°®ÆÐÐÂÒ©Îïɸѡ¹ÜÀíϵͳ
ÓÉ°®ÆÐÐÂÒ½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾¿ª·¢µÄÒ©Îïɸѡ¹ÜÀíϵͳÊÇÒ»¿î×ÛºÏÐéÄâɸѡÓëʵÌåɸѡµÄÒ©ÎïɸѡÊý¾Ý¹ÜÀíϵͳ£¬ÄÚÖû¯ºÏÎï×ÊÔ´¿â£¬Îª´ó¹æÄ£»¯ºÏÎï¸ßͨÁ¿É¸Ñ¡ÌṩÊý¾Ý¹ÜÀíһվʽ½â¾ö·½°¸£¬¼Ó¿ìÒ©Îï·¢ÏÖ£¬ÏµÍ³ÕûºÏÐéÄâɸѡ¡¢ÊµÌåɸѡ¼°»¯ºÏÎï×ÊÔ´Èý´óÄ£¿é£¬Êý¾ÝÏ໥¹ØÁª¡£»ùÓÚÏàËÆÐÔÔÀí£¬´Ó»¯ºÏÎï×ÊÔ´¿âÖвéÕÒÏàËÆ»¯ºÏÎ´Ó¶ø½øÐÐÉúÎïʵÑéÑéÖ¤£¬²¢½«É¸Ñ¡Êý¾Ýͨ¹ýʵÌåɸѡģ¿é¹ÜÀí£¬Ò»¸ö»îÐÔ»¯ºÏÎï·¢ÏÖ¶à¸ö»îÐÔ»¯ºÏÎʵÏÖһվʽ¿ÆÑÐÊý¾Ý¹ÜÀí¡£
Ëü¾ßÓÐÈçϹ¦ÄÜ£º
1¡¢Ò©ÎïÐéÄâɸѡ
Ìṩ¿ìËÙ¸ßЧµÄÒ©ÎïÐéÄâɸѡ¹¦ÄÜ£¬Ã¿Ãë¿Éɸѡ 20 Íò¸ö»¯Ñ§½á¹¹£»»ùÓÚ·Ö×Ó¶þάºÍÈýάÏàËÆÁ½ÖÖ·½·¨£¬Ò»¸ö»îÐÔ»¯ºÏÎï·¢ÏÖ¶à¸ö»îÐÔ»¯ºÏÎ¼ÓËÙÒ©Îï·¢ÏÖ£»Ò»¼üÌá½»£¬É¸Ñ¡¸ßЧ£¬Ëٶȿ죬ȫ³Ì¿É×·ËÝ¡£
2¡¢Ò©ÎïʵÌåɸѡ
¶Ô»¯ºÏÎï¼°ÆäÉúÎï»îÐÔɸѡÊý¾Ý½øÐйÜÀí£¬Ö§³Ö·Ö×Óˮƽ¡¢Ï¸°ûˮƽ¡¢¶¯ÎïˮƽµÈ²»Í¬²ã´ÎÒ©ÎïɸѡµÄÊý¾Ý¹ÜÀí£»ÌṩҩÎïʵÌåɸѡÐÅÏ¢´æ´¢Óë²éѯģ¿é£¬¿ÉÁé»îÅäÖÃÏà¹ØÄ£¿éµÄ×Ö¶ÎÐÅÏ¢£¬½øÐÐʵÌåɸѡÐÅÏ¢µÄ±ã½Ý´æ´¢Óë¿ìËÙ²éѯ¡£
3¡¢»¯ºÏÎï×ÊÔ´¿â
ÄÚÖû¯ºÏÎï×ÊÔ´¿â£¬°üÀ¨Ò©Îï¿â£¬ÌìÈ»²úÎï¿â£¬ºÏ³É»¯ºÏÎï¿âµÈ£¬ÎÞ·ì¶Ô½Ó»¯ºÏÎ﹩ӦÉÌ£¬ÎªÓû§¹ºÂò»¯ºÏÎïÌṩ±ã½Ý·þÎñ£»Ò²Ö§³Ö¹ÜÀí±¾µØ»¯ºÏÎï×ÊÔ´¿â¡£
4¡¢ÍŶӹÜÀí
ÍŶÓÓÉ´´½¨ÈË´´½¨£¬ÍŶӳÉÔ±ÓɹÜÀíÔ±´´½¨²¢Í³Ò»¹ÜÀí£»ÍŶÓ×ÊÔ´¼°ÆäɸѡÐÅÏ¢ÓÉÍŶÓͳһ¹ÜÀí£¬È¨ÏÞ·ÖÃ÷£¬Êý¾Ý°²È«¡£
¼¼ÊõÓÅÊÆ
1£©Ò©Îïɸѡ¹ÜÀíϵͳºËÐļ¼Êõ»ùÓÚ·Ö×ÓÈýάÐÎ×´µþºÏËã·¨£¨wega£©ÒÑ»ñµÃÃÀ¹úרÀûÊÚȨ£¨us 9,811,642 b2£©£¬yan, x.µÈ[2]·¢±íµÄÎÄÕÂÖ¤Ã÷Æ侫¶È¸ßÓÚͬÀàËã·¨£»
2£©ËüÊǼ¯ÐéÄâɸѡÓëʵÌåɸѡÊý¾Ý¹ÜÀíÓÚÒ»Ì壬ʵÏÖin silico£¬in vitro£¬in vivoÒ©ÎïɸѡÊý¾Ý¹ÜÀí£¬ÌṩҩÎïɸѡһվʽ·þÎñ£»
3£©·½±ã¹ÜÀíÓëÐ×÷£¬Ö§³ÖÉè¼Æ¡¢ºÏ³É¡¢ÉúÎïµÈ¶àÍŶÓÐ×÷£¬Êý¾Ý¹²Ïí£¬È¨ÏÞ·ÖÃ÷£»
4£©Êý¾Ý°²È«£¬²ÉÓÃ×îеÄÊý¾Ý¼ÓÃܼ¼Êõ£¬Õ˺ŵǼ£¬È¨ÏÞ¿ØÖÆ£¬È«·½Î»±£ÕÏÊý¾Ý°²È«£»
5£©Ïà¶Ô¹úÍâ²úÆ·£¬½çÃæÇåÎú£¬·ûºÏ¹úÈËʹÓÃÏ°¹ß£»
6£©¹ú²ú×ÔÖ÷¿ª·¢£¬±ÜÃâ¼¼Êõ·âËø£¨Ä㶮µÄ£©¡£
ÐéÄâɸѡ×÷Ϊ¼ÆËã»ú¸¨ÖúÒ©ÎïÉè¼ÆÖеÄÒ»ÏîʵÓû¯¼¼Êõ£¬ÔÚµ±´úµÄ´´ÐÂÒ©ÎïÑз¢Öз¢»Ó×ÅÖØÒªµÄ×÷Ó᣶øÈô˵ҩÎïÉè¼ÆÕýÔÚ·¢Õ¹ÖУ¬ÄÇÒ©Îïɸѡ¹ÜÀíϵͳ¾ÍÊǸøËüÌáËٶȣ¬ËüÄÒÀ¨ÁËÐéÄâɸѡºÍʵÌåɸѡÊý¾Ý¹ÜÀí£¬×éÖ¯ÑϽ÷£¬È¨ÏÞÃ÷È·£¬½ÇÉ«·ÖÃ÷£¬´ó´óÌá¸ßÒ©ÎïɸѡЧÂÊ£¬¼Ó¿ìÐÂÒ©Ñз¢¡£
²Î¿¼ÎÄÏ×
[1]t.n.doman,et al.,molecular docking and high-throughput screening for novel inhibitors ofprotein tyrosine phosphatase-1b. journal of medicinal chemistry, 2002, 45: 2213-21
[2]yan, x.et al., enhancing molecular shape comparison by weighted gaussian functions.journal of chemical information and modeling 2013, 53, (8), 1967-78
ϵͳ·ÃÎÊÍøÖ· http://demo.dsms.iprexmed.com/#/index
ϵͳ¿ªÍ¨ÇëÁªÏµ¿Í·þ
΢ÐÅ 18928913950
qq 2277165792
µç»° 020-28100562
΢ÐÅ¿Í·þ
[ last edited by kspm20225 on 2018-12-17 at 11:05 ]
[ Last edited by kspm20225 on 2019-6-18 at 19:06 ] |